Clinical Trials
7
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2016
Completed
3
42.9%
Not yet recruiting
1
14.3%
Recruiting
1
14.3%
Terminated
2
28.6%
No approval data available
- Shattuck Labs raised up to $103 million in an oversubscribed private placement led by OrbiMed to fund development of SL-325, a potential first-in-class DR3 blocking antibody for autoimmune diseases. - The funding will support multiple Phase 2 clinical trials of SL-325 in inflammatory bowel disease and other autoimmune conditions, with Phase 1 enrollment expected to begin in Q3 2025. - SL-325 targets the Death Receptor 3 (DR3) pathway and preclinical studies demonstrate superior activity over TL1A antibodies, potentially offering improved efficacy and reduced immunogenicity. - Combined with existing cash, the financing is expected to fund operations through 2029 and advance the company's lead program targeting TNF superfamily receptors.
- Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts. - Companies are shifting from broad R&D portfolios to focused pipeline optimization, with firms like Shattuck Labs and Relay Therapeutics narrowing their therapeutic focus to core projects with highest potential returns. - The layoffs reflect strategic responses to investor pressure for capital discipline, post-pandemic demand shifts, and the need to extend cash reserves while maintaining progress on lead clinical programs. - Industry consolidation and increased outsourcing to contract research organizations are driving operational realignment, as companies seek to reduce overhead costs and access specialized expertise without maintaining high-cost facilities.
- Shattuck Labs' SL-325, a DR3 blocking antibody, showed no adverse effects at doses up to 100 mg/kg in non-human primate toxicology studies, marking a significant milestone for inflammatory bowel disease treatment. - The preclinical study demonstrated complete and sustained DR3 receptor occupancy across all tested doses, with no toxicity or agonistic effects observed in cynomolgus macaques. - The company plans to advance SL-325 to Phase 1 clinical trials following an anticipated IND filing in Q3, supported by favorable pharmacokinetic profiles suggesting potential for extended dosing intervals.
- Shattuck Labs anticipates GLP toxicology study data readout for SL-325, a DR3 blocking antibody, in Q1 2025, supporting its development for inflammatory diseases. - The company plans to file an IND for SL-325 in Q3 2025 and initiate a Phase 1 clinical trial in the same quarter, marking significant progress. - Shattuck expects to nominate a lead DR3 bispecific development candidate in H2 2025, expanding its pipeline in TNF superfamily receptor therapeutics. - With $90.1 million in cash as of September 2024, Shattuck Labs projects funding operations into 2027, beyond the Phase 1 trial results.
- Shattuck Labs discontinues the clinical program for SL-172154 after modest survival improvements in TP53m AML and HR-MDS patients compared to azacitidine monotherapy. - The company will now focus on SL-325, a first-in-class DR3 antagonist antibody, targeting the TL1A/DR3 signaling pathway for inflammatory bowel disease (IBD) treatment. - An Investigational New Drug (IND) application for SL-325 is expected to be filed in Q3 2025, with preclinical studies showing high affinity binding and superior efficacy over TL1A antibodies. - Restructuring, including a 40% workforce reduction, extends Shattuck's cash runway into 2027, supporting the development of SL-325 through Phase 1 clinical trials.
